JUPITER NEUROSCIENCES, INC. (JUNS): debt financing — Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing

JUPITER NEUROSCIENCES, INC.

Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.
Additional $2M pre-paid advance contingent on registration statement and stockholder approval; total $6M pre-paid.
Up to $14M available under SEPA over 24 months subject to conditions; proceeds to fund Phase 2 Parkinson's trial and Nugevia growth.
Yorkville receives 131,909 commitment shares and $25K structuring fee; issuance subject to 19.99% Exchange Cap unless stockholder approval obtained.
Convertible notes bear 8% interest, mature Oct 24, 2026; repayment via cash or advance notices under SEPA.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

JUPITER NEUROSCIENCES, INC. incurred convertible notes of $4.0 million with YA II PN, LTD.

Instrument: convertible notes
Principal: $4.0 million
Counterparty: YA II PN, LTD
Event: incurrence

Exact text from the filing

The first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October 27, 2025, in exchange for the Company’s issuance to Yorkville of a Convertible Note in the principal amount of $4.0 million, which was issued with an “original issue discount” (“OID”) of 7.0% (or $280,000) and is initially convertible into Common Stock at a fixed conversion price of $1.50 per share (subject to adjustment as provided in such Convertible Note) (the “First Convertible Note”).

View on SEC.gov

304 debt financings filed in the last 30 days. Browse all debt financings →

JUPITER NEUROSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-019783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.